GDTC Logo

CytoMed Therapeutics Limited - Ordinary Shares (GDTC) Stock Forecast & Price Prediction

Live GDTC Stock Price & Analysis

Home โ€บ Stocks โ€บ Singapore | NASDAQ | Healthcare | Biotechnology

$2.56

+0.06 (2.40%)

12 Month Price Forecast For GDTC

$2.56
Current Price
$29.54M
Market Cap
1 Ratings
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to GDTC Price Forecasts

+95.3%
To High Target of $5.00
+95.3%
To Median Target of $5.00
+95.3%
To Low Target of $5.00

GDTC Price Momentum

-8.9%
1 Week Change
+16.9%
1 Month Change
+2.0%
1 Year Change
-24.7%
Year-to-Date Change
-36.8%
From 52W High of $4.05
+113.3%
From 52W Low of $1.20

๐Ÿค” Considering CytoMed (GDTC)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 15, 2025 3:09 PM UTC

GDTC Analyst Ratings & Price Targets

Based on our analysis of 1 Wall Street analyst, GDTC has a bullish consensus with a median price target of $5.00 (ranging from $5.00 to $5.00). Currently trading at $2.56, the median forecast implies a 95.3% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.

The most optimistic forecast comes from Bruce Jackson at Benchmark, projecting a 95.3% upside. Conversely, the most conservative target is provided by Bruce Jackson at Benchmark, suggesting a 95.3% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

GDTC Analyst Consensus

1
Buy
0
Hold
0
Sell

GDTC Price Target Range

Low
$5.00
Average
$5.00
High
$5.00
Current: $2.56

Latest GDTC Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for GDTC.

Date Firm Analyst Rating Change Price Target
Oct 10, 2024 Benchmark Bruce Jackson Speculative Buy Reiterates $5.00
Jun 11, 2024 Benchmark Bruce Jackson Speculative Buy Reiterates $5.00
Dec 4, 2023 Benchmark Bruce Jackson Speculative Buy Reiterates $5.00
Jul 21, 2023 Benchmark Bruce Jackson Speculative Buy Initiates $5.00

Stocks Similar to CytoMed Therapeutics Limited - Ordinary Shares

The following stocks are similar to CytoMed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

CytoMed Therapeutics Limited - Ordinary Shares (GDTC) Financial Data

CytoMed Therapeutics Limited - Ordinary Shares has a market capitalization of $29.54M with a P/E ratio of -6.6x. The company generates $334,185 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is -21.1% quarter-over-quarter, while maintaining an operating margin of -736.0% and return on equity of -26.3%.

Valuation Metrics

Market Cap $29.54M
Enterprise Value $16.76M
P/E Ratio -6.6x
PEG Ratio -17.1x
Price/Sales 66.0x

Growth & Margins

Revenue Growth (YoY) -21.1%
Gross Margin N/A
Operating Margin -736.0%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +23.1%
Current Ratio 21.5x
Debt/Equity 4.2x
ROE -26.3%
ROA -17.4%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

CytoMed Therapeutics Limited - Ordinary Shares logo

CytoMed Therapeutics Limited - Ordinary Shares (GDTC) Company Overview

About CytoMed Therapeutics Limited - Ordinary Shares

What They Do

Develops cell-based immunotherapies for cancer.

Business Model

The company focuses on developing innovative immunotherapy products, particularly targeting cancers and degenerative diseases. Its revenue model includes collaborations and research agreements with healthcare institutions and other organizations to advance clinical trials and product development.

Additional Information

CytoMed Therapeutics is in the pre-clinical stage and is currently advancing its lead product candidates through clinical trials. The company has strategic partnerships with Sengkang General Hospital and SunAct Cancer Institute to enhance its research capabilities and expand its therapeutic offerings. Established in 2018, it operates primarily in Malaysia and Singapore.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

0

CEO

Dr. Wee Kiat Tan Ph.D.

Country

Singapore

IPO Year

2023

CytoMed Therapeutics Limited - Ordinary Shares (GDTC) Latest News & Analysis

GDTC stock latest news image
Quick Summary

CytoMed Therapeutics (NASDAQ: GDTC) announced a shareholder letter from its Chairman, anticipating full-year audited results by the end of April 2025. Shareholders are encouraged to read it.

Why It Matters

The announcement signals upcoming full-year results, potentially impacting stock performance and investor sentiment based on financial health and future outlook.

Source: GlobeNewsWire
Market Sentiment: Neutral
GDTC stock latest news image
Quick Summary

CytoMed Therapeutics GDTC stock has decreased by 6.35%, trading at $3.23 as of the latest update on Monday.

Why It Matters

The 6.35% drop in CytoMed Therapeutics GDTC stock indicates potential concerns over company performance or market sentiment, impacting investor confidence and future stock valuations.

Source: Benzinga
Market Sentiment: Negative
GDTC stock latest news image
Quick Summary

The 74th Emerging Growth Conference is set for August 21-22, 2024, as announced by EmergingGrowth.com, a key platform for small cap investment insights.

Why It Matters

The Emerging Growth Conference could provide insights into small-cap investment opportunities, influencing market trends and potential stock performance for attendees.

Source: GlobeNewsWire
Market Sentiment: Neutral
GDTC stock latest news image
Quick Summary

CytoMed has been granted another patent for its allogeneic iPSC-derived hybrid gamma delta natural killer T cells technology, enhancing its intellectual property portfolio.

Why It Matters

The patent enhances CytoMed's competitive edge in the biotech sector, potentially leading to increased market value and attracting investor interest in innovative cancer therapies.

Source: GlobeNewsWire
Market Sentiment: Neutral
GDTC stock latest news image
Quick Summary

CytoMed Therapeutics has received board approval for a pilot program to isolate and cryo-store PBMCs for loyal shareholders, starting June 1, 2024. This aligns with its strategy for allogeneic therapies.

Why It Matters

CytoMed's pilot program for cryo-storing PBMCs could enhance shareholder loyalty and attract investment, while advancing their innovative cancer therapies, potentially increasing company valuation.

Source: GlobeNewsWire
Market Sentiment: Neutral
GDTC stock latest news image
Quick Summary

CytoMed Therapeutics (NASDAQ:GDTC) has entered a research collaboration with Sengkang General Hospital to develop allogeneic cell-based immunotherapies for cancer treatment.

Why It Matters

The collaboration with Sengkang General Hospital may enhance CytoMed's research capabilities and credibility, potentially accelerating product development and attracting investment interest.

Source: Accesswire
Market Sentiment: Neutral

Frequently Asked Questions About GDTC Stock

What is CytoMed Therapeutics Limited - Ordinary Shares's (GDTC) stock forecast for 2025?

Based on our analysis of 1 Wall Street analysts, CytoMed Therapeutics Limited - Ordinary Shares (GDTC) has a median price target of $5.00. The highest price target is $5.00 and the lowest is $5.00.

Is GDTC stock a good investment in 2025?

According to current analyst ratings, GDTC has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.56. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for GDTC stock?

Wall Street analysts predict GDTC stock could reach $5.00 in the next 12 months. This represents a 95.3% increase from the current price of $2.56. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is CytoMed Therapeutics Limited - Ordinary Shares's business model?

The company focuses on developing innovative immunotherapy products, particularly targeting cancers and degenerative diseases. Its revenue model includes collaborations and research agreements with healthcare institutions and other organizations to advance clinical trials and product development.

What is the highest forecasted price for GDTC CytoMed Therapeutics Limited - Ordinary Shares?

The highest price target for GDTC is $5.00 from Bruce Jackson at Benchmark, which represents a 95.3% increase from the current price of $2.56.

What is the lowest forecasted price for GDTC CytoMed Therapeutics Limited - Ordinary Shares?

The lowest price target for GDTC is $5.00 from Bruce Jackson at Benchmark, which represents a 95.3% increase from the current price of $2.56.

What is the overall GDTC consensus from analysts for CytoMed Therapeutics Limited - Ordinary Shares?

The overall analyst consensus for GDTC is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $5.00.

How accurate are GDTC stock price projections?

Stock price projections, including those for CytoMed Therapeutics Limited - Ordinary Shares, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.